Nivolumab Plus Ipilimumab Displays Durable Benefit in MSI-H/dMMR mCRC
July 8th 2022
Nivolumab alone or in combination with ipilimumab continued to demonstrate sustained clinical benefit as second- and first-line therapy, respectively, in patients with microsatellite instability–high and mismatch repair deficient metastatic colorectal cancer.